Fluorouracil

Generic Name
Fluorouracil
Brand Names
Actikerall, Carac, Efudex, Fluoroplex, Tolak
Drug Type
Small Molecule
Chemical Formula
C4H3FN2O2
CAS Number
51-21-8
Unique Ingredient Identifier
U3P01618RT
Background

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication

For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions
Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
Associated Therapies
-
Clinical Trials
Related News

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

First Posted Date
2020-04-01
Last Posted Date
2024-07-18
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
49
Registration Number
NCT04329494
Locations
🇺🇸

Northwell Health Cancer Institute at Huntington, Greenlawn, New York, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

City of Hope Medical Center, Duarte, California, United States

Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

First Posted Date
2020-03-17
Last Posted Date
2023-11-13
Lead Sponsor
National Cancer Institute, Naples
Target Recruit Count
200
Registration Number
NCT04310176
Locations
🇮🇹

Istituto Tumori di Napoli - Fondazione G. Pascale, Napoli, Campania, Italy

Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

First Posted Date
2020-03-06
Last Posted Date
2023-08-08
Lead Sponsor
Shanghai Henlius Biotech
Target Recruit Count
131
Registration Number
NCT04297995
Locations
🇨🇳

Shanghai Henlius Biotech Inc., Shanghai, Shanghai, China

Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients

First Posted Date
2020-02-13
Last Posted Date
2020-02-13
Lead Sponsor
Jessa Hospital
Target Recruit Count
250
Registration Number
NCT04269369

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

First Posted Date
2020-01-30
Last Posted Date
2024-11-05
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
314
Registration Number
NCT04248452
Locations
🇺🇸

Mercy Cancer Center-West Lakes, Clive, Iowa, United States

🇺🇸

Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

🇺🇸

Henry Ford Saint John Hospital - Academic, Grosse Pointe Woods, Michigan, United States

and more 448 locations

A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer

First Posted Date
2020-01-30
Last Posted Date
2022-03-11
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
264
Registration Number
NCT04247984
Locations
🇨🇳

Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China

Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer

First Posted Date
2020-01-29
Last Posted Date
2024-11-14
Lead Sponsor
Vejle Hospital
Target Recruit Count
83
Registration Number
NCT04245865
Locations
🇩🇰

Department of Oncology, Vejle Hospital, Vejle, Denmark

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

First Posted Date
2020-01-18
Last Posted Date
2023-12-28
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
176
Registration Number
NCT04233866
Locations
🇺🇸

Mount Carmel East Hospital, Columbus, Ohio, United States

🇺🇸

Wake Forest Baptist Health - Hematology Oncology - Statesville, Statesville, North Carolina, United States

🇺🇸

Neurosurgeons of New Jersey-Ridgewood, Ridgewood, New Jersey, United States

and more 756 locations

Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.

First Posted Date
2020-01-18
Last Posted Date
2020-01-18
Lead Sponsor
Baruch Brenner
Target Recruit Count
31
Registration Number
NCT04229459
Locations
🇮🇱

Rabin Medical Center, Petach Tikva, Israel

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

First Posted Date
2020-01-02
Last Posted Date
2024-11-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
95
Registration Number
NCT04216290
Locations
🇺🇸

Springfield Memorial Hospital, Springfield, Illinois, United States

🇺🇸

Logan Health Medical Center, Kalispell, Montana, United States

🇺🇸

Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States

and more 214 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy